Humacyte Q2 net loss $22.7M; vascular trauma trial enrollment complete, BLA on track

Humacyte, Inc.

2023-Q2 EPS reported -$0.58

Completed enrollment in Phase 2/3 V005 trauma trial (68 patients, 51 for efficacy); top-line results expected Q3 2023.
BLA filing for HAV in vascular trauma planned Q4 2023; received RMAT designation in May 2023.
Cash $114.6M; up to $160M Oberland funding ($40M received); funds operations past potential approval.
Net loss $22.7M vs net income $36.9M in Q2 2022; increase due to non-cash remeasurement of contingent earnout.
Ukraine humanitarian program: 19 patients, 95% 30-day patency, 100% limb salvage, 0 infections.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Humacyte, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-23-000112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.